Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Rhea-AI Summary
Dogwood Therapeutics (Nasdaq:DWTX) announced it will report third quarter 2025 financial results on Thursday, November 6, 2025 before market open.
The company is a development-stage biotechnology firm focused on new medicines to treat pain and neuropathy. No financial metrics or guidance were included in the announcement.
Positive
- None.
Negative
- None.
News Market Reaction – DWTX
On the day this news was published, DWTX gained 7.78%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $16M at that time. Trading volume was above average at 1.5x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and neuropathy, announced today that it will report third quarter 2025 financial results on Thursday, November 6, 2025, before the open of the financial markets.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.
Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the Food and Drug Administration ("FDA") for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP").
SP16 IV is a low-density lipoprotein receptor related protein-1 (LRP1) agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.
For more information, please visit www.dwtx.com.
Forward-Looking Statements
Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Contact:
CORE IR
(516) 222-2560
IR@dwtx.com
SOURCE: Dogwood Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Dogwood Therapeutics (DWTX) report Q3 2025 results?
What time will Dogwood Therapeutics (DWTX) release its November 6, 2025 earnings?
Will Dogwood Therapeutics (DWTX) provide financial details in the November 6, 2025 release?
How can investors access Dogwood Therapeutics (DWTX) Q3 2025 results on November 6, 2025?
What is Dogwood Therapeutics (DWTX) focused on commercially and clinically?
